rs61754393
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM1PM5PP2PP3PP5_Very_Strong
The NM_000372.5(TYR):c.1265G>A(p.Arg422Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000366 in 1,611,886 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R422W) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000372.5 missense
Scores
Clinical Significance
Conservation
Publications
- oculocutaneous albinism type 1Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- oculocutaneous albinism type 1AInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), Laboratory for Molecular Medicine
- Waardenburg syndrome type 2Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- minimal pigment oculocutaneous albinism type 1Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- oculocutaneous albinism type 1BInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- temperature-sensitive oculocutaneous albinism type 1Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000198 AC: 3AN: 151780Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000599 AC: 15AN: 250424 AF XY: 0.0000296 show subpopulations
GnomAD4 exome AF: 0.0000384 AC: 56AN: 1459988Hom.: 0 Cov.: 31 AF XY: 0.0000413 AC XY: 30AN XY: 726336 show subpopulations
GnomAD4 genome AF: 0.0000198 AC: 3AN: 151898Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74246 show subpopulations
ClinVar
Submissions by phenotype
not provided Pathogenic:2Other:1
Published functional studies demonstrate a damaging effect with decreased tyrosine hydroxylase, dopa oxidase, DHI oxidase, copper-binding and/or catalytic activities (PMID: 1900309, 9242509, 1429711); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 1900309, 32552135, 10987646, 1900307, 1429711, 11284711, 9242509, 24392141, 27775880, 1943686, 18326704, 29437493, 31077556, 15146472, 2567165, 38145795, 36729443, 37605172, 34838614, 38542347) -
- -
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 422 of the TYR protein (p.Arg422Gln). This variant is present in population databases (rs61754393, gnomAD 0.02%). This missense change has been observed in individual(s) with ocular albinism (PMID: 1900309, 31077556). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 3782). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt TYR protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects TYR function (PMID: 1900309). For these reasons, this variant has been classified as Pathogenic. -
Oculocutaneous albinism type 1B Pathogenic:1
- -
Oculocutaneous albinism type 1A Pathogenic:1
- -
Temperature-sensitive oculocutaneous albinism type 1 Pathogenic:1
- -
TYR-related disorder Pathogenic:1
The TYR c.1265G>A variant is predicted to result in the amino acid substitution p.Arg422Gln. This variant has been reported in the compound heterozygous states in multiple individuals with oculocutaneous albinism (see for examples: Giebel et al. 1991. PubMed ID: 1900309; Zhong et al. 2019. PubMed ID: 31077556; Chuan et al. 2021. PubMed ID: 32552135). An alternate substitution of this amino acid (p.Arg422Trp) has also been reported in individuals with oculocutaneous albinism (King et al 2003. PubMed ID: 13680365). Functional studies have shown that the p.Arg422Gln substitution affects protein function (Toyofuku et al. 2001. PubMed ID: 11284711; Dolinska. 2014. PubMed ID: 24392141). This variant is reported in 0.022% of alleles in individuals of East Asian descent in gnomAD. This variant has been classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/3782/). Given the evidence, we interpret this variant as pathogenic. -
SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN Pathogenic:1
- -
Oculocutaneous albinism type 1B;C4551504:Oculocutaneous albinism type 1A Pathogenic:1
PM2_Supporting+PM3_VeryStrong+PP4+PP3 -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at